MetLife Investment Management’s LENZ Therapeutics LENZ Stock Holding History

MetLife Investment Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$89.6K	Hold	9,787	–	–	﹤0.01%	2584
2025 Q4	$157K	Hold	9,787	–	–	﹤0.01%	2396
2025 Q3	$456K	Sell	9,787 -1,153	-11%	-$42.4K	﹤0.01%	1852
2025 Q2	$321K	Buy	10,940 +3,281	+43%	+$89.3K	﹤0.01%	1918
2025 Q1	$197K	Sell	7,659 -13	-0.2%	-$320	﹤0.01%	2211
2024 Q4	$221K	Hold	7,672	–	–	﹤0.01%	2255
2024 Q3	$182K	Buy	+7,672	New	+$170K	﹤0.01%	2334
2022 Q2	–	Sell	-2,878	Closed	-$103K	–	2912
2022 Q1	$103K	Buy	+2,878	New	+$180K	﹤0.01%	2619
2021 Q4	–	Sell	-980	Closed	-$112K	–	2560
2021 Q3	$112K	Buy	+980	New	+$145K	﹤0.01%	2392

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

MetLife Investment Management's LENZ Position: Q1 2026 in Review

MetLife Investment Management held its LENZ Therapeutics (LENZ) position steady in Q1 2026 at 9,787 shares worth $89.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2584.

MetLife Investment Management first reported a position in LENZ in Q3 2021 and has held it in 9 quarters since. The position peaked at $456K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

MetLife Investment Management held 9,787 shares of LENZ Therapeutics worth $89.6K as of Q1 2026.
MetLife Investment Management left its LENZ Therapeutics share count unchanged in Q1 2026.
LENZ Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2584 holding.
MetLife Investment Management first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 9 quarters since.
MetLife Investment Management's LENZ Therapeutics position peaked at $456K in Q3 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.